A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease.
• Signed Informed Consent Form.
• Age ≥ 18 years.
• For women of childbearing potential, use of accepted and effective method of non-hormonal contraception.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Ability and capacity to comply with study and follow-up procedures.
• For anthracycline cohort only: Adequate left ventricular function at study entry, defined as a left ventricular ejection fraction (LVEF) ≥ 50% by either multigated acquisition (MUGA) scan scan or echocardiography (ECHO).
• For subjects who have received recent radiation therapy, recovery prior to baseline (Day 0) from any significant (Grade ≥ 3) acute toxicity.

Exclusion Criteria:

• Unknown human epidermal growth factor receptor 2 (HER2) status or known HER2-positive status.
• Prior chemotherapy for locally recurrent or metastatic disease.
• Prior hormonal therapy less than 1 week prior to Day 0.
• Prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0.
• For anthracycline cohort only: Prior anthracycline as part of neoadjuvant or adjuvant therapy for localized breast cancer.
• Investigational therapy within 28 days of Day 0.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
• Minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to Day 0.
• Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial growth factor (VEGF) pathway-targeted therapy.
• Known brain or other central nervous system (CNS) metastases.
• Blood pressure of > 150/100 mmHg.
• Unstable angina.
• New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF).
• History of myocardial infarction within 6 months prior to Day 0.
• History of stroke or transient ischemic attack within 6 months prior to Day 0.
• Clinically significant peripheral vascular disease.
• Evidence of bleeding diathesis or coagulopathy.
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
• Serious non-healing wound, ulcer, or bone fracture.
• Pregnancy (positive serum pregnancy test) or lactation.
• Inadequate organ function, as evidenced by any of the following laboratory values: Absolute neutrophil count < 1500/uL; platelet count < 100,000/uL; total bilirubin > 1.5 mg/dL; alkaline phosphatase, AST, and/or ALT > 2x upper limit of normal (ULN) (> 5x ULN in subjects with known liver or, for alkaline phosphatase elevations, bone involvement); alkaline phosphatase > 2x ULN (> 7x ULN in subjects with known bone involvement); serum creatinine > 2.0 mg/dL; partial thromboplastin time (PTT) and/or either international normalized ratio (INR) or prothrombin time (PT) > 1.5x upper limit of normal (except for subjects receiving anti-coagulation therapy); urine protein/creatinine ratio > 1.0 at screening for U.S. subjects, or urine dipstick for proteinuria >/= 1+ at screening followed by 24-hour urine collection demonstrating > 1 g protein/24 hr for ex-U.S. subjects.
• Uncontrolled serious medical or psychiatric illness.
• Active infection requiring intravenous (iv) antibiotics at Day 0.
• History of other malignancies within 5 years of Day 0 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix (subjects with a history of bilateral breast cancer will be eligible).